Multicenter, pilot study of telbivudine (LdT) anti-HBV treatment prior to the initiation of highly active antiretroviral therapy containing lamivudine in subjects coinfected with HBV and HIV.

Trial Profile

Multicenter, pilot study of telbivudine (LdT) anti-HBV treatment prior to the initiation of highly active antiretroviral therapy containing lamivudine in subjects coinfected with HBV and HIV.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 18 May 2012

At a glance

  • Drugs Telbivudine (Primary) ; Antiretrovirals; Lamivudine
  • Indications Hepatitis B; HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Apr 2012 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov
    • 28 Sep 2008 Primary outcome added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top